Investors > News Releases
Mar 30, 2020
Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer
Products
Mar 23, 2020
Myriad Announces Board of Directors Leadership Transition
Corporate
Mar 18, 2020
NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer
Products
Feb 14, 2020
New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy
Products
Feb 12, 2020
Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference
Corporate
Feb 11, 2020
Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer
Pipeline
Feb 06, 2020
Myriad Announces Leadership Transition
Corporate
Feb 06, 2020
Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results
Financial
Jan 30, 2020
Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020
Corporate
Jan 22, 2020
Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer
Pipeline
Jan 21, 2020
Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer
Pipeline
Jan 14, 2020
Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology
Corporate
Jan 06, 2020
Myriad Genetics to Present at the J.P. Morgan 2020 Healthcare Conference
Corporate
Jan 06, 2020
New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study
Products
Dec 30, 2019
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer
Pipeline